Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
HZNP was delisted on the 5th of October, 2023.
233 hedge funds and large institutions have $2.57B invested in Horizon Therapeutics Public Limited Company Ordinary Shares in 2016 Q3 according to their latest regulatory filings, with 61 funds opening new positions, 73 increasing their positions, 71 reducing their positions, and 25 closing their positions.
246% more call options, than puts
Call options by funds: $155M | Put options by funds: $44.9M
144% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 25
18% more funds holding
Funds holding: 198 → 233 (+35)
14% more funds holding in top 10
Funds holding in top 10: 7 → 8 (+1)
11% more capital invested
Capital invested by funds: $2.31B → $2.57B (+$252M)
3% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 71
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HM
HealthCor Management
New York
|
+$83M |
| 2 |
CCM
Consonance Capital Management
New York
|
+$72.3M |
| 3 |
KCM
Kingdon Capital Management
New York
|
+$54M |
| 4 |
GT
Glenmede Trust
Philadelphia,
Pennsylvania
|
+$40.1M |
| 5 |
Goldman Sachs
New York
|
+$36.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$207M |
| 2 |
DM
Deerfield Management
New York
|
-$143M |
| 3 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
-$57.8M |
| 4 |
TCM
TimesSquare Capital Management
New York
|
-$28.3M |
| 5 |
BC
Broadfin Capital
New York
|
-$26.6M |
HZNP Hedge Fund Activity: Q3 2016 in Review
233 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) for Q3 2016, worth a combined $2.57B — up 11% from $2.31B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new HZNP positions and 25 closed out — a net gain of 36 holders — while 73 added to existing stakes and 71 trimmed.
The largest buyer was HealthCor Management, opening a new position worth an estimated $83M. The largest seller was Fidelity Investments, cutting an estimated $207M.
- 233 institutional investors held Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) as of Q3 2016, up from 198 in Q2 2016.
- Funds reported $2.57B of Horizon Therapeutics Public Limited Company Ordinary Shares stock for Q3 2016, up 11% quarter-over-quarter.
- 61 funds opened new Horizon Therapeutics Public Limited Company Ordinary Shares positions in Q3 2016 and 25 closed out, a net change of +36 holders.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares buyer in Q3 2016 was HealthCor Management, an estimated $83M added.
- The largest Horizon Therapeutics Public Limited Company Ordinary Shares seller in Q3 2016 was Fidelity Investments, an estimated $207M sold.
Based on aggregated 13F filings for Q3 2016.